- Home
- THTX vs RVPH Comparison
THTX vs RVPH Comparison
Compare THTX & RVPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- THTX
- RVPH
- Stock Information
- Founded
- THTX 1993
- RVPH 2006
- Country
- THTX Canada
- RVPH United States
- Employees
- THTX N/A
- RVPH N/A
- Industry
- THTX Biotechnology: Pharmaceutical Preparations
- RVPH Biotechnology: Pharmaceutical Preparations
- Sector
- THTX Health Care
- RVPH Health Care
- Exchange
- THTX Nasdaq
- RVPH Nasdaq
- Market Cap
- THTX 93.3M
- RVPH 87.6M
- IPO Year
- THTX N/A
- RVPH N/A
- Fundamental
- Price
- THTX $1.72
- RVPH $1.77
- Analyst Decision
- THTX Hold
- RVPH Strong Buy
- Analyst Count
- THTX 1
- RVPH 5
- Target Price
- THTX N/A
- RVPH $12.00
- AVG Volume (30 Days)
- THTX 178.5K
- RVPH 3.3M
- Earning Date
- THTX 02-19-2025
- RVPH 11-14-2024
- Dividend Yield
- THTX N/A
- RVPH N/A
- EPS Growth
- THTX N/A
- RVPH N/A
- EPS
- THTX N/A
- RVPH N/A
- Revenue
- THTX $84,316,000.00
- RVPH N/A
- Revenue This Year
- THTX $5.78
- RVPH N/A
- Revenue Next Year
- THTX $2.47
- RVPH N/A
- P/E Ratio
- THTX N/A
- RVPH N/A
- Revenue Growth
- THTX 5.75
- RVPH N/A
- 52 Week Low
- THTX $1.08
- RVPH $0.60
- 52 Week High
- THTX $2.18
- RVPH $4.83
- Technical
- Relative Strength Index (RSI)
- THTX 50.28
- RVPH 49.95
- Support Level
- THTX $1.69
- RVPH $1.56
- Resistance Level
- THTX $1.83
- RVPH $1.86
- Average True Range (ATR)
- THTX 0.13
- RVPH 0.25
- MACD
- THTX -0.04
- RVPH -0.03
- Stochastic Oscillator
- THTX 19.30
- RVPH 34.43
About THTX Theratechnologies Inc.
Theratechnologies Inc is a specialty pharmaceutical company that addresses the unmet medical needs of HIV patients. It mainly operates in Canada and the United States. The company has two approved products, EGRIFTA marketed in Canada and the United States, and Trogarzo approved for commercialization in the United States. It generates revenue from one customer RxCrossroads, which is domiciled in the United States.
About RVPH Reviva Pharmaceuticals Holdings Inc.
Reviva Pharmaceuticals Holdings Inc is a late-stage pharmaceutical company that discovers, develops, and seeks to commercialize therapeutics for diseases. The current pipeline of the company focuses on the central nervous system, inflammatory, and cardiometabolic diseases. The company uses a chemical genomics-driven technology platform and proprietary chemistry to develop new medicines. The company's pipeline currently has two drug candidates, Brilaroxazine (RP5063) which is intended to treat multiple neuropsychiatric indications, including schizophrenia, bipolar disorder, depressive disorder, attention-deficit/hyperactivity disorder, behavioral and psychotic symptoms of dementia or Alzheimer's disease, and Parkinson's disease psychosis and its other drug candidate is RP1208.